Japan's Senju licenses Eyenovia ophthalmic therapy for sale Asia-wide

Japan's Senju Pharmaceutical has licensed U.S.-based Eyenovia's portfolio of microdosed ophthalmic treatments to develop and market throughout Asia. Financial arrangements were not disclosed, but the global market for such drugs is $19 billion.

As part of the agreement, Senju agreed to join an investment syndicate with three venture companies and cover its own research and development costs in Asia.

Eyenovia has developed clinical-stage microdosing technology and markets it as significantly improving bioavailability, efficacy and safety of existing eye drugs without requiring chemical reformulation.

- here's the release